Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
While promising, PD-L1 expression on tumor tissues as assessed by immunohistochemistry has been shown to be an imperfect biomarker that only applies to a limited number of cancers, whereas many patients with PD-L1-negative tumors still respond to anti-PD-(L)1 immunotherapy. Recent studies using pati...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI AG
2022-05-01
|
| シリーズ: | Biomedicines |
| 主題: | |
| オンライン・アクセス: | https://www.mdpi.com/2227-9059/10/5/1181 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|
